Skip to main content
TickerPosts
IOVAIovancebiotechnologyclinical trialstock newslung cancer

Iovance Stock Falls 35% as Investors Weigh Updated Lung-Cancer Data

Steven Levine1 min read
Scientist handling samples for research in a modern laboratory.
Illustrative photo by Polina Tankilevitch on Pexels

Iovance Biotherapeutics (NASDAQ: IOVA) shares fell about 35% on Thursday, October 29, as investors digested updated data for lifileucel, the company's tumor-infiltrating lymphocyte therapy being studied in previously treated non-squamous metastatic non-small-cell lung cancer. The full update added detail to results that Iovance had described as positive the previous evening, according to historical share-price data.

The overall response rate was little changed

In the updated analysis, 17 of 69 patients responded, for an objective response rate of 24.6%. That was consistent with the previously reported 25.6% rate among 39 patients, according to Iovance's release.

The company also reported a higher response rate in a subgroup of 22 patients defined by KRAS wild-type status, HER2 wild-type status and a history of smoking. Thirteen patients in that subgroup responded, for a 59.1% rate. Iovance said the subgroup was identified retrospectively, so the result is a reason for further study rather than proof that the same response rate will hold in a prospectively selected group.

Iovance plans a prospective test

The company plans to begin enrollment in November in POSITILITY, a biomarker-enriched cohort within the ongoing Phase 2 program. Iovance said the study is designed with registrational intent and that the broader cohorts support a planned supplemental biologics license application in 2027. Any filing and regulatory outcome remain subject to future data and FDA feedback.

The share-price decline followed a sharp reversal from the initial after-hours reaction to the first announcement. The overall response rate was consistent with the prior readout, while the new subgroup analysis was retrospective; the day's move alone does not reveal how investors weighed each element.

Follow the IOVA discussion on TickerPosts for later trial and company updates.

Published October 29, 2026. Lifileucel is investigational for this lung-cancer use. This article is informational and is not investment advice.

Sources